| Course | NR 568 Advanced Pharmacology for the Adult-Gerontology Primary Care Nurse Practitioner |
|---|---|
| Week | 4 |
| Paper type | Prescribing case analysis |
| Length | About 1,130 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Adult-Gerontology Primary Care NP (AGPCNP) |
| Updated | October 2026 |
Free sample paper for NR 568 Week 4
Prescribing Case Analysis: Raising Allopurinol Above the Old Kidney-Based Ceiling for a 79-Year-Old With Two Gout Flares a Year and a Clearance of 33, With the Working Shown
Student Name
College of Nursing, Chamberlain University
NR 568: Advanced Pharmacology for the Adult-Gerontology Primary Care Nurse Practitioner
Instructor Name
Month Day, Year
Prescribing Case Analysis: Raising Allopurinol Above the Old Kidney-Based Ceiling for a 79-Year-Old With Two Gout Flares a Year and a Clearance of 33, With the Working Shown
The Problem
The composite patient followed through this course has had two gout flares this year, each affecting the right first metatarsophalangeal joint and lasting about a week. The patient has taken allopurinol 300 mg daily for four years, prescribed by a rheumatologist. Serum urate last month was 8.1 mg/dL. Guidance for patients on urate-lowering therapy sets the urate goal under 6 and asks prescribers to climb toward it rather than settle on a fixed dose (FitzGerald et al., 2020). The question is whether and how to raise allopurinol in a patient with stage 3b chronic kidney disease.
The Estimate as Visible Working
Creatinine clearance is estimated with the Cockcroft-Gault equation, because most drug labels and older dosing tables are indexed to it.
Clearance equals 140 less the age, multiplied by weight in kilograms, with that product divided by 72 multiplied by the creatinine.
= (140 minus 79) times 70 kg, divided by (72 times 1.8 mg/dL)
= 61 times 70, divided by 129.6
= 4,270 divided by 129.6
= about 33 mL/min.
The laboratory also reports an estimated glomerular filtration rate of 36 mL/min/1.73 m2 from the CKD-EPI equation. The two numbers are close here, but they answer different questions: the eGFR describes kidney function standardized to body surface area for staging, while Cockcroft-Gault estimates clearance for this person's body for drug dosing.
Which Weight Went In
The patient weighs 70 kg and is 175 cm tall. Ideal body weight for a man of that height is about 70.5 kg, so actual and ideal weights are essentially the same and actual weight is used. In a patient with obesity, using actual weight would overestimate clearance, and an adjusted weight would be chosen and stated.
Amount or Interval
The older approach set a maximum allopurinol dose according to creatinine clearance, which for this patient would have suggested roughly 150 to 200 mg daily, below what the patient already takes. Current guidance rejects that ceiling. The rheumatology guideline recommends starting allopurinol at a low dose in chronic kidney disease and then titrating upward, including above the old kidney-based maximum, to reach the urate target, with monitoring (FitzGerald et al., 2020). The risk of allopurinol hypersensitivity syndrome is linked mainly to a high starting dose relative to kidney function, not to gradual increases after a low start (Stamp et al., 2012). Because the patient has tolerated 300 mg for four years, the hypersensitivity concern at this stage is low.
The change is in the amount, not the interval. Allopurinol is taken once daily, and its active metabolite, oxypurinol, has a long half-life that lengthens in kidney disease, so a daily dose remains appropriate.
Order: increase allopurinol from 300 mg to 400 mg once daily (one 300 mg tablet and one 100 mg tablet), then to 500 mg after four weeks if urate remains above 6 mg/dL and the patient has no rash.
Flare Prophylaxis
Raising urate-lowering therapy can trigger flares as crystals mobilize. The guideline advises covering the first three to six months of any start or increase with a flare-preventing agent (FitzGerald et al., 2020). Colchicine 0.3 mg once daily is chosen, a reduced dose because of the clearance and because the patient takes atorvastatin, which raises the risk of myopathy with colchicine. Nonsteroidal drugs are excluded because of the kidney disease, lisinopril and chlorthalidone (American Geriatrics Society Beers Criteria Update Expert Panel, 2023). Low-dose prednisone is the alternative if colchicine causes diarrhea.
The First Dose Exception
Some drugs need a full first dose whatever the kidney is doing, since how much fills the body is a question about distribution, not removal. Allopurinol is the opposite: the guideline's approach is to start low in kidney disease. That distinction matters for this patient's other prescriptions too. If the patient needed an antibiotic loading dose for a serious infection, it would be given in full, while maintenance doses would be adjusted.
Where No Adjusted Dose Exists
Febuxostat is the main alternative urate-lowering drug. It has limited data at clearance below 30 mL/min and carries a boxed warning about cardiovascular death in patients with established cardiovascular disease, and this patient had a coronary stent nine years ago. For that reason, febuxostat is not the next step if allopurinol fails. Pegloticase is reserved for refractory gout. Where a drug has no adjusted dose for a given clearance, the analysis treats that as a reason to prefer another drug, not to guess a dose.
Thiazide Contribution
Chlorthalidone raises serum urate by reducing its excretion, and it may be contributing to the flares. Switching blood pressure therapy, for example to losartan, which modestly lowers urate, would be considered with the patient's cardiologist, but it is not done in the same month as the allopurinol change, so that each effect can be judged on its own.
Diet and Other Contributors
Medication is not the only lever. The patient drinks two beers most evenings during the summer and eats red meat several times a week. Alcohol, particularly beer, and purine-rich foods raise urate, and limiting them supports the medication. The rheumatology guideline suggests limiting alcohol and purine intake for people with gout (FitzGerald et al., 2020). These suggestions are offered alongside the dose change, not instead of it, because diet alone rarely lowers urate enough to stop flares in someone who already needs allopurinol.
What the Patient Is Told
The patient hears: the gout medicine is being raised slowly because the urate level is still too high; a small dose of colchicine will prevent flares while that happens; the dose is safe for your kidneys because we are going up in small steps and checking your blood; stop the allopurinol and call at once for a rash, fever or mouth sores; and keep taking it during a flare, because stopping it then makes things worse.
The plan is reviewed with the patient's rheumatologist by message.
The Value Drawn on a Named Day
Serum urate, serum creatinine and liver enzymes are drawn on 3 November, four weeks after the increase, and again four weeks after any further increase. A complete blood count is drawn at the same time because of the colchicine. The patient is told to stop allopurinol immediately and call for any rash, fever or mouth sores, since these can signal hypersensitivity.
References
American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372
FitzGerald, J. D., Dalbeth, N., Mikuls, T., BrignardelloâPetersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., Levy, G., Libbey, C., Mount, D., Pillinger, M. H., Rosenthal, A., Singh, J. A., Sims, J. E., Smith, B. J., Wenger, N. S., . . . Neogi, T. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180
Stamp, L. K., Taylor, W. J., Jones, P. B., Dockerty, J. L., Drake, J., Frampton, C., & Dalbeth, N. (2012). Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis & Rheumatism, 64(8), 2529-2536. https://doi.org/10.1002/art.34488
Reading the NR 568 Week 4 instructions
The prescribing case analysis usually asks you to defend a drug choice and dose for a patient with reduced kidney function. Expect the prompt to ask for the clearance estimate, the dose adjustment, alternatives and monitoring. Show the equation and every step of the calculation, and say which weight you used and why. Explain whether the adjustment changes the amount, the interval or both. Note any drug where the first dose is given in full regardless of kidney function, and any drug with no adjusted dose at this level of function. Cite current guidance for the dosing approach, especially where it has changed. Name the laboratory value you will check and the date you will draw it.
How this NR 568 Week 4 example is built
The sample states the problem, two flares and a urate of 8.1 on 300 mg, and the target below 6. The clearance is calculated step by step to about 33 mL/min and compared with the laboratory's eGFR. Actual weight is used because it matches ideal weight. A section explains that the old kidney-based maximum has been replaced by titration to target, with hypersensitivity linked mainly to high starting doses, so the dose rises to 400 mg once daily. Colchicine 0.3 mg is added for prophylaxis, with nonsteroidal drugs excluded. Sections cover the first-dose exception, febuxostat's limits, the thiazide's effect on urate, diet, patient teaching and a urate, creatinine and liver panel drawn on 3 November.
Reading the NR 568 Week 4 grading rubric
Case analyses at this point in the course are usually marked on correct and visible arithmetic, the right weight, a clear statement of whether amount or interval changes, current dosing guidance and a dated monitoring plan. A dose set from a figure never calculated loses the most, so every step of the clearance estimate is shown. Stating the weight used, and why, prevents a common error in patients with obesity. Recognizing that the old allopurinol ceiling has been replaced by titration shows current knowledge and carries significant weight. Reduced-dose colchicine with its reason shows attention to interactions. Explaining when no adjusted dose exists, as with febuxostat here, shows judgment. Naming the date of the next urate turns monitoring into an order. Guideline citations support the approach.
Common NR 568 Week 4 mistakes, and how to avoid them
Arithmetic causes the largest losses in this paper: a dose set from an unstated clearance, or a calculation done with the wrong weight. Another frequent problem is announcing an adjustment without saying whether the amount or the interval changes. Many papers still apply the old kidney-based allopurinol maximum, which current guidance has moved away from. Some forget that certain drugs need a full first dose regardless of kidney function. Others leave monitoring as ongoing labs with no date. Show the equation, state the weight, name the lever, follow current guidance and put a date on the next level. A case for another drug and kidney level can be worked through from your patient's values.
Get a NR 568 Week 4 example written to your instructions
Send the Week 4 case with the laboratory values and the regimen your section supplies, plus any required element list, and a custom example is written to those figures and returned inside 24 to 48 hours, free the first time. The estimate is shown as working rather than asserted, so every line of it can be followed.
More NR 568 papers and AGPCNP samples
- NR 568 Week 1: Citalopram Dose Discussion Post
- NR 568 Week 2: Medication List Review
- NR 568 Week 3: Clarithromycin Interaction Analysis
- NR 568 Week 5: Deprescribing Plan
- NR 568 Week 6: Adverse Effect Write-up
- NR 568 Week 7: Polypharmacy Case Study
- NR 568 Week 8: Pharmacotherapy Synthesis
NR 568 Week 4 questions, answered
Which estimate of kidney function should the paper use?
Whichever one your classroom or your dosing reference specifies, used consistently and named. Most drug references built their adjustment tables against a creatinine clearance estimate while charts commonly report a different figure altogether, so swapping one for the other quietly changes the dose with no error visible on the page. State the estimate, the inputs behind it, and the source that pairs it with the table you used.
Does the analysis have to change the drug as well as the dose?
Often it does not, and pretending otherwise weakens the paper. A great many agents remain the right choice in reduced function and simply need different arithmetic, and showing that is a legitimate answer to the case. The switch gets argued only where the adjusted regimen would still be unsafe, or where the agent carries a threshold rather than a reduction. Say which of those two you are in and the reasoning becomes easy to follow.
How is impaired liver function handled when no equation exists for it?
By judgment, stated openly as judgment. The kidney hands you a figure and a table; the liver hands you a grading system, a few laboratory values and no arithmetic that converts them into a dose. A strong answer names the handling step that is affected, chooses a lower starting amount for that reason, and sets an earlier recheck precisely because the safety net of a calculated figure is not available here.
Where can I find a free NR 568 Week 4 sample paper?
The allopurinol case above, with the clearance worked out line by line and the next urate dated, is the full NR 568 Week 4 sample. Send another kidney dosing case for a worked version.
Can allopurinol go above the kidney-based dose in NR 568 Week 4?
Yes. Current rheumatology guidance starts low in kidney disease and then titrates to a urate below 6, even above older clearance-based maximums, with monitoring.